Healthcare stocks: 5 catalysts powering India’s 2026 run

Why healthcare is back in focus

Indian healthcare stocks have seen multiple triggers in quick succession, spanning policy announcements, brokerage upgrades, and quarterly results. The move has not been limited to one sub-sector, with pharmaceuticals, diagnostics, and hospitals all featuring in daily market leadership. In several sessions, healthcare stocks traded higher even as broader markets saw selling pressure. The underlying theme across updates is higher demand for treatments and services, plus improving visibility on government-supported healthcare spending. Investors have also been tracking hospital capacity additions and better pricing, often reflected in improving average revenue per occupied bed (ARPOB). Against this backdrop, brokerage reports have added to the momentum by naming preferred picks and raising targets on select names.

Motilal Oswal’s top picks for domestic healthcare growth

Motilal Oswal Wealth Management flagged robust growth in the domestic healthcare sector and identified five stocks as its preferred ways to play the theme. The list includes Lupin, Mankind Pharma, Piramal Pharma, Ipca Labs, and Max Healthcare. Separately, Motilal Oswal also initiated coverage on two healthcare sector stocks, Inventurus Knowledge Solutions (IKS) and Sagility. The brokerage said both could deliver more than 30% return from current levels. It also said these two companies have the strongest EPS growth rate among its coverage, calling it a positive sign for investors.

Dr Lal PathLabs rises after a Kotak double upgrade

Dr Lal PathLabs gained after Kotak Institutional Equities issued a double upgrade on the stock. Shares were trading at Rs 2,234.65, up nearly 5% from the previous close. Kotak’s revised price target implies an upside of 8% from the March 22 closing level. The move highlighted how broker rating changes can quickly drive price discovery in diagnostics, especially when valuations and earnings visibility are being reassessed.

Narayana Hrudayalaya hits a record high on Q2 strength

Narayana Hrudayalaya rallied 9% to a record high on robust Q2 results. In the past three months, the stock has surged 15% versus a flat move in the benchmark Sensex. The reaction underscored continued investor preference for hospital operators when earnings outcomes reinforce demand strength and operating leverage.

Nifty healthcare breadth improves, Apollo results in focus

In one session, excluding Sun Pharmaceutical Industries, all other Nifty 50 healthcare-related stocks were up. Apollo Hospitals Enterprise was cited as the biggest gainer after its net profit surged in the December quarter. Dr. Reddy’s Laboratories rose 1% and Cipla was up 0.4% in the same session. Apollo’s operational performance was described as strong across segments, with multiple business lines recording healthy year-on-year growth.

Apollo Hospitals segment revenues show double-digit growth

Apollo Hospitals’ consolidated revenue from the healthcare services segment grew over 15% year-on-year to INR 32.25 billion. Revenue from the retail health and diagnostics business grew around 20% year-on-year to INR 4.67 billion in the December quarter. Its digital health and pharmacy distribution top line rose over 20% year-on-year to INR 28.28 billion. These numbers were used in market coverage to explain why hospital operators and integrated healthcare platforms have remained in focus during earnings season.

Budget 2026-27: medical hubs, tourism push, Biopharma SHAKTI

Healthcare shares also reacted to policy signals from the Union Budget for 2026-27 (Apr-Mar). Finance Minister Nirmala Sitharaman proposed a scheme to support states in establishing five regional medical hubs in partnership with the private sector. The hubs are planned as integrated healthcare complexes combining medical, educational, and research facilities, and are set to include AYUSH Centres, Medical Value Tourism Facilitation Centres, and diagnostics, post-care, and rehabilitation infrastructure. The Budget also proposed promoting medical tourism and “Heal in India” in partnership with the private sector, along with capacity building and easier visa norms. For biopharma manufacturing, the finance minister proposed Biopharma SHAKTI (Strategy for Healthcare Advancement through Knowledge, Technology and Innovation) with an outlay of INR 100 billion over the next five years to support domestic production of biologics and biosimilars.

CGHS package rate revision triggers a hospital-stock rally

Hospital stocks rallied after the government announced a revision of Central Government Health Services (CGHS) package rates, with revised rates applicable from October 13. Another update described the change as the first major overhaul since 2014, revising rates for nearly 2,000 medical procedures. In market trading around the announcement, Apollo Hospitals rose as much as 3.8%, Max Healthcare gained 4%, Fortis Healthcare surged 4.8%, Narayana Hrudayalaya climbed 3.2%, and Yatharth Hospital and Trauma Care jumped 5% in morning trade. Separate price action details also showed Apollo rising up to 3.7% to Rs 7,730, Fortis up 5% to Rs 1,027, and Global Health touching Rs 1,347 with gains of just over 1%. The revision was framed as reopening a channel that had become stagnant and could support smoother cashless operations for participating private hospitals.

Stock-specific snapshots and sector fundamentals cited by analysts

Some stock profiles and fundamentals have also been highlighted alongside the broader sector narrative. Thyrocare Technologies was described as a pioneer in diagnostic and preventive healthcare with ROCE of 18.75% and a debt-to-equity ratio of 0.04. Zydus Lifesciences was described as a leading pharmaceutical company across generics, vaccines, and APIs, with market capitalisation of INR 1,015.69 billion (Rs 1,01,569.26 crore) as of January 9, 2025, and ROE of 20.52%. Lupin was noted for its generics, biosimilars, and specialty portfolio, with ROCE of 16.24% and trailing twelve months EPS of Rs 57.57 as of January 9, 2025. Alongside company-specific metrics, sector drivers cited include rising population, growing health awareness, government schemes such as Ayushman Bharat, rising public health budgets, and increasing prevalence of non-communicable diseases such as diabetes and cardiovascular conditions.

Market impact and what investors are tracking

The healthcare sector, including pharmaceuticals and hospitals, delivered a strong performance in the March 2025 quarter. The pharmaceutical segment benefited from increased demand in chronic therapies in the domestic formulations market and steady growth in the US generics business. Hospitals were supported by expanded bed capacity and robust growth in ARPOB, as per analyst commentary in the provided material. Analysts also pointed to potential in the CDMO space, with a BNP Paribas report citing investor feedback that India could benefit as global innovators diversify supply chains away from China, while also noting concerns around high valuations and limited near-term earnings visibility. In hospitals, cited growth drivers include lifestyle diseases, improving affordability and accessibility supported by higher disposable incomes, a demand-supply gap, medical tourism, increased insurance penetration affecting payer mix, and expansion by private players. An IBEF estimate pegged the Indian hospital market to grow at 8% CAGR between 2022-23 and 2031-32 to reach $193.6 billion.

Key data points at a glance

Exposure to government schemes: who could benefit more

Conclusion

Healthcare stocks have been supported by a combination of policy initiatives, earnings outcomes, and brokerage positioning, with both pharma and hospitals featuring prominently. Budget 2026-27 proposals around regional medical hubs, medical tourism, and Biopharma SHAKTI added a policy layer to the sector narrative. The CGHS rate revision, effective October 13, provided a separate catalyst focused on hospital pricing and participation in government schemes. In the near term, investors are likely to keep tracking the implementation of policy proposals, the roll-out of revised CGHS rates, and quarterly execution across hospitals, diagnostics, and domestic pharma franchises.